Why use AAD measures
What are the different types of measures for MIPS reporting?
There are two different categories of quality measures for reporting: MIPS measures and QCDR measures. Both can be used for MIPS reporting.
MIPS measures are measures that are approved by CMS to be included in the Quality Payment Program (QPP). Each year, CMS specifies the dermatology specialty measure set. CMS does not require dermatologists to report these measures, but they are designed to align well with dermatology practice. Any eligible clinician is able to select these measures for use in MIPS.
QCDR measures are measures that a medical specialty creates and are approved by CMS for reporting in MIPS. However, these QCDR measures are not available for everyone. QCDR measures can only be reported on if you report through the QCDR that owns/licenses those measures. The AAD offers DataDerm to report dermatology-specific QCDR measures.
Within both of these categories, there are AAD measures, which are quality measures created and maintained by the AAD.
Number | Name | Description |
|---|---|---|
AAD 6 | Skin Cancer: Biopsy Reporting Time – Clinician to Patient | Percentage of patients with skin biopsy specimens with a diagnosis of cutaneous basal or squamous cell carcinoma or melanoma (including in situ disease) or primary cutaneous malignancies who are notified of their final biopsy pathology findings within less than or equal to 10 days from the time the biopsy was performed. |
AAD 7 | Psoriasis: Screening for Psoriatic Arthritis | Percentage of patients with diagnosis of psoriasis who are screened for psoriatic arthritis at each visit. |
AAD 8 | Chronic Skin Conditions: Patient Reported Quality-of-Life | The percentage of patients aged 18 years and older with a chronic skin condition whose self-assessed quality-of-life was recorded at least once in the medical record within the measurement period. |
| AAD 12 | Melanoma: Appropriate Surgical Margins | Percentage of primary excisional surgeries for melanoma or melanoma in situ with Breslow depth and appropriate surgical margins per the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology- Melanoma (NCCN Guideline). |
| AAD 14 | Melanoma: Tracking and Evaluation of Recurrence | Percentage of patients who had an excisional surgery for melanoma or melanoma in situ with initial AJCC staging of 0, I, or II, in the past 5 years in which the operating provider examines and/or diagnoses the patient for recurrence of melanoma. |
| AAD 15 | Psoriasis – Appropriate Assessment & Treatment of Severe Psoriasis | Percentage of patients with a diagnosis of psoriasis with a documented Body Surface Area (BSA) greater than 10% for whom phototherapy or an oral systemic or biologic medication was prescribed. |
AAD 16 | Avoidance of Post-operative Systemic Antibiotics for Office-based Closures and Reconstruction After Skin Cancer Resection Procedures | Percentage of procedures in patients aged 18 and older with a diagnosis of skin cancer who underwent intermediate layer or complex linear closure or reconstruction after skin cancer resection in the office-based setting who were prescribed post-operative systemic antibiotics to be taken immediately following reconstruction surgery. (Inverse measure.) |
AAD 17 | Continuation of Anticoagulation Therapy in the Office-based Setting for Closures and Reconstruction After Skin Cancer Resection Procedures | Percentage of procedures in patients, aged 18 and older with a diagnosis of skin cancer, on prescribed anticoagulation therapy, who had intermediate layer and/or complex linear closures OR reconstruction after skin cancer resection performed in the office-based setting where anticoagulant therapy was continued prior to surgery. |
AAD 18 | Avoidance of Opioid Prescriptions for Closures and Reconstruction After Skin Cancer Resection | Percentage of procedures in patients, aged 18 and older with a diagnosis of skin cancer, who had intermediate layer and/or complex linear closures OR reconstruction after skin cancer resection where opioid/narcotic therapy was prescribed as first line therapy (as defined by a prescription in anticipation of or at time of surgery) for post-operative pain management by the reconstructing surgeon. (Inverse measure.) |
| AAD 19 | Psoriasis – Shared Decision Making in the Treatment of Psoriasis | Percentage of patients with a diagnosis of psoriasis with a documented shared decision-making discussion that includes the patient’s treatment goals, preferences, and the risks & benefits of treatment options. |
Related Academy resources
Access a step-by-step guide to help you avoid a penalty and earn an incentive.
Find the quality measures that best fit your practice.
Explore the Academy's resources on Quality and patient safety.
